Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Gilead Sciences (NQ: GILD )

106.38 UNCHANGED
Streaming Delayed Price Updated: 4:15 PM EDT, Apr 23, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 14
Open 106.38
Bid (Size) 106.22 (1)
Ask (Size) 107.08 (1)
Prev. Close 106.38
Today's Range 106.38 - 106.38
52wk Range 62.07 - 119.96
Shares Outstanding 1,253,809,440
Dividend Yield 2.97%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Gilead Cancer Drug Combined With Merck's Drug Effective In Difficult To Treat Type Of Breast Cancer
Gilead's Trodelvy and Merck's Keytruda improved progression-free survival in PD-L1+ metastatic TNBC in a Phase 3 trial with no new safety concerns. 
Via Benzinga
Gilead Announces Positive Results From Trodelvy-Keytruda Combo Study For Breast Cancer: But Retail’s Unmoved
Triple-negative breast cancer accounts for approximately 15% of all breast cancers and has a higher chance of recurrence. 
Via Stocktwits

Performance

YTD
+15.78%
+15.78%
1 Month
-0.34%
-0.34%
3 Month
+14.34%
+14.34%
6 Month
+21.95%
+21.95%
1 Year
+58.71%
+58.71%

More News

Read More
Trodelvy® Plus Keytruda® Demonstrates a Statistically Significant and Clinically Meaningful Improvement in Progression Free Survival in Patients With Previously Untreated PD-L1+ Metastatic Triple-Negative Breast Cancer
From Gilead Sciences, Inc.
Via Business Wire
Why Quality Investors May Find GILEAD SCIENCES INC (NASDAQ:GILD) Attractive.
Via Chartmill
Earnings Scheduled For April 24, 2025
Via Benzinga
P/E Ratio Insights for Gilead Sciences
Via Benzinga
Gilead Sciences's Options Frenzy: What You Need to Know
Via Benzinga
Exploring Gilead Sciences's Earnings Expectations
Via Benzinga
Gilead Sciences (GILD) To Report Earnings Tomorrow: Here Is What To Expect
Via StockStory
Topics Artificial Intelligence
Exposures Artificial Intelligence
Assessing Gilead Sciences: Insights From 15 Financial Analysts
Via Benzinga
2 High-Yielding ETFs Retirees Can Safely Build Their Portfolios Around
Via The Motley Fool
Topics ETFs Economy World Trade
Exposures Economy Tariff
Time 100 Most Influential People Includes Elon Musk, Mark Zuckerberg, Alex Karp And More Public Company CEOs
Via Benzinga
Trump's New Order Targets Drug Pricing Transparency And Medicare Cost Reduction
Via Benzinga
Topics Government
Exposures Political
3 Reasons GILD is Risky and 1 Stock to Buy Instead
Via StockStory
Topics Stocks
Exposures COVID-19 US Equities
Is Iovance Biotherapeutics a Millionaire-Maker?
Via The Motley Fool
Exposures Product Safety
Eli Lilly, AbbVie, Bristol Myers, Regeneron, And Other Pharma Companies Slide As Donald Trump Confirms Tariffs On Pharma Companies
Via Benzinga
Topics Government World Trade
Exposures Political Tariff
Gilead Sciences to Release First Quarter 2025 Financial Results on Thursday, April 24, 2025
From Gilead Sciences, Inc.
Via Business Wire
S&P, Dow Jones Pharma Names Rattled — Again — On Trump's Tariffs Whiplash
Via Investor's Business Daily
Topics Government Stocks World Trade
Exposures Political Tariff US Equities
Rule Breaker Investing: Essays From Yesterday, Vol. 7
Via The Motley Fool
Pharma Industry Faces Jitters As Trump Hints At Historic Tariffs, BofA Outlines Probable Timeline
Via Benzinga
Topics Government Supply Chain World Trade
Exposures Political Supply Chain Tariff
Stay updated with the S&P500 stocks that are on the move in today's pre-market session.
Via Chartmill
Dow Jones, S&P 500 Pharma Names Slammed As New Trump Tariffs Target Drug Imports
Via Investor's Business Daily
Topics Government Stocks World Trade
Exposures Political Tariff US Equities
2 Top Dividend Stocks That Could Set You Up for Life
Via The Motley Fool
Topics Government Initial Public Offering Intellectual Property
Exposures Intellectual Property Political Securities Market
Vertex, Alnylam Best Positioned As Biopharma Braces For Tariff Impact, Goldman Sachs Flags Regeneron, Biogen Risks
Via Benzinga
Topics Government World Trade
Exposures Political Tariff
Amazon, Alphabet, KLA And A Health Care Stock On CNBC's 'Final Trades'
Via Benzinga
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.